Literature DB >> 21263264

Stereotactic ablative radiation therapy for primary lung tumors.

John H Heinzerling1, Brian Kavanagh, Robert D Timmerman.   

Abstract

Stereotactic ablative radiotherapy, also known as stereotactic body radiation therapy, has been developed as an innovative therapy for stage I non-small cell lung cancer and has now emerged as a standard treatment option for medically inoperable patients through careful analysis utilizing prospective, multi-institutional trials. This article reviews and updates the evidence for use of stereotactic ablative radiotherapy in medically inoperable patients with stage I lung cancer, its extension of use to medically operable patients, and the toxicities associated with this emerging technique.

Entities:  

Mesh:

Year:  2011        PMID: 21263264     DOI: 10.1097/PPO.0b013e31820a7f80

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  10 in total

Review 1.  Novel radiotherapy approaches for lung cancer: combining radiation therapy with targeted and immunotherapies.

Authors:  Charles B Simone; Stuart H Burri; John H Heinzerling
Journal:  Transl Lung Cancer Res       Date:  2015-10

2.  Effective Rat Lung Tumor Model for Stereotactic Body Radiation Therapy.

Authors:  Zhang Zhang; Michelle Wodzak; Olivier Belzile; Heling Zhou; Brock Sishc; Hao Yan; Strahinja Stojadinovic; Ralph P Mason; Rolf A Brekken; Rajiv Chopra; Michael D Story; Robert Timmerman; Debabrata Saha
Journal:  Radiat Res       Date:  2016-05-25       Impact factor: 2.841

3.  Stereotactic ablative radiotherapy for small lung tumors with a moderate dose. Favorable results and low toxicity.

Authors:  V Duncker-Rohr; U Nestle; F Momm; V Prokic; F Heinemann; M Mix; J Reusch; M-B Messmer; N Marschner; C F Waller; W A Weber; A-L Grosu
Journal:  Strahlenther Onkol       Date:  2013-01       Impact factor: 3.621

4.  Changes in the Secretory Profile of NSCLC-Associated Fibroblasts after Ablative Radiotherapy: Potential Impact on Angiogenesis and Tumor Growth.

Authors:  Turid Hellevik; Ingvild Pettersen; Vivian Berg; Jack Bruun; Kristian Bartnes; Lill-Tove Busund; Anthony Chalmers; Roy Bremnes; Iñigo Martinez-Zubiaurre
Journal:  Transl Oncol       Date:  2013-02-01       Impact factor: 4.243

5.  Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced.

Authors:  Turid Hellevik; Ingvild Pettersen; Vivian Berg; Jan Olof Winberg; Bjørn T Moe; Kristian Bartnes; Ruth H Paulssen; Lill-Tove Busund; Roy Bremnes; Anthony Chalmers; Iñigo Martinez-Zubiaurre
Journal:  Radiat Oncol       Date:  2012-04-13       Impact factor: 3.481

6.  Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers.

Authors:  Kedar Hastak; Steven Bhutra; Renate Parry; James M Ford
Journal:  Oncotarget       Date:  2017-04-18

7.  A new function for the serine protease HtrA2 in controlling radiation-induced senescence in cancer cells.

Authors:  Liat Hammer; Vered Levin-Salomon; Naama Yaeli-Slonim; Moria Weiss; Naama P Dekel-Bird; Tsviya Olender; Ziv Porat; Sabina Winograd-Katz; Alon Savidor; Yishai Levin; Shani Bialik; Benjamin Geiger; Adi Kimchi
Journal:  Mol Oncol       Date:  2022-02-16       Impact factor: 6.603

Review 8.  Radiotherapy and the tumor stroma: the importance of dose and fractionation.

Authors:  Turid Hellevik; Iñigo Martinez-Zubiaurre
Journal:  Front Oncol       Date:  2014-01-21       Impact factor: 6.244

9.  Preliminary comparison of the registration effect of 4D-CBCT and 3D-CBCT in image-guided radiotherapy of Stage IA non-small-cell lung cancer.

Authors:  Zhibo Tan; Chuanyao Liu; Ying Zhou; Weixi Shen
Journal:  J Radiat Res       Date:  2017-11-01       Impact factor: 2.724

Review 10.  The utilization of immunotherapy with radiation therapy in lung cancer: a narrative review.

Authors:  John H Heinzerling; Kathryn F Mileham; Charles B Simone
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 0.496

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.